Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTERNTerns Pharmaceuticals$3.96+1.9%$3.02$1.87▼$11.40$344.54M-0.181.50 million shs165,453 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTERNTerns Pharmaceuticals0.00%+4.86%+34.72%+19.38%-52.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTERNTerns Pharmaceuticals4.1093 of 5 stars3.32.00.04.12.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63295.07% UpsideCurrent Analyst Ratings BreakdownLatest TERN, SDV, CHIB, and FWT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.004/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.003/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTERNTerns Pharmaceuticals-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)Latest TERN, SDV, CHIB, and FWT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipTERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTERNTerns Pharmaceuticals4087.34 million72.11 millionNot OptionableTERN, SDV, CHIB, and FWT HeadlinesRecent News About These CompaniesTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 14 at 3:44 AM | marketbeat.comNASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsightJune 13 at 8:31 PM | theglobeandmail.com3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comBank of America Corp DE Purchases 138,661 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)June 7, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 98,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 31, 2025 | marketbeat.comTerns Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 29, 2025 | globenewswire.comInfinitum Asset Management LLC Takes $1.11 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 28, 2025 | marketbeat.comTerns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potentialMay 27, 2025 | investing.comNuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 27, 2025 | marketbeat.comNorthern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 26, 2025 | marketbeat.comDeutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 25, 2025 | marketbeat.comVR Adviser LLC Sells 2,332,968 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Position Cut by Point72 Asset Management L.P.May 22, 2025 | marketbeat.comCubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) is Soleus Capital Management L.P.'s 10th Largest PositionMay 21, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Graham Capital Management L.P.May 17, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 16, 2025 | marketbeat.comTerns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701May 14, 2025 | globenewswire.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%May 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBuybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsTERN, SDV, CHIB, and FWT Company DescriptionsTerns Pharmaceuticals NASDAQ:TERN$3.96 +0.08 (+1.93%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
